USA – A Temporary Fix for the EpiPen Crisis?

FDA has applied a bandage to help with the EpiPen shortage, but Mylan could have competition looming on the horizon from Teva Pharmaceuticals, a Petah, Tikvah, Israel-based firm that received approval for a generic form of the product earlier this month.

The ongoing saga of the EpiPen shortage crisis took a new turn today as FDA made a move to extend the expiration dates of certain lots of the allergy drug-device combo by four months.

The recent EpiPen shortage has caused FDA to extend the expiration dates of certain lots of the allergy drug-device combo by four months. The products effected are the EpiPen 0.3 mg Auto-Injectors and its authorized generic version. This measure by FDA was made after a review of stability data.

Mylan’s product treats life-threatening allergic reactions by automatically injecting a dose of epinephrine, also known as adrenaline. The company developed the drug-device combo and partnered with Pfizer’s Meridian Medical technologies to manufacture the product…